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Hepatic ﬁbrosisAbstract HCV is a worldwide problem and the need to assess the degree of ﬁbrosis is the corner
stone in its treatment. Liver biopsy has been used for years to assess the degree of ﬁbrosis and activ-
ity but recently many non-invasive methods have emerged to replace it as aspartate transami-
nase/platelet ratio [APRI), abdominal ultrasonography measuring caudate/right lobe ratio and
hepatic stiffness [Fibroscan).
Purpose: Correlate the accuracy of Transient Elastography [Fibroscan) in comparison to liver
biopsy as a non-invasive method for ﬁbrosis assessment in chronic hepatitis C patients.
Methods: The study was done on 50 patients with chronic HCV [32 males and 18 females) for
which liver biopsy and ﬁbroscan were performed.
Results: There was positive correlation of liver biopsy with ﬁbroscan score, there was moderate
agreement [matching) between liver biopsy and ﬁbroscan the lowest matching were in F0 and the
highest were in F3.
Conclusion: Fibroscan has a good matching with liver biopsy in the detection of hepatic ﬁbrosis
and follow up of its progression.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic hepatitis C (HCV) is a global health problem that
affects more than 170 million people worldwide (1), particu-
larly in Egypt, where high prevalence rates were reported
294 A.H.K. Abdelmaksoud et al.reaching up to 20% (2). Diagnosis and treatment of patients
with chronic hepatitis mostly rely on the staging of liver ﬁbro-
sis. Antiviral therapy is proposed if moderate to severe
(METAVIR stages F2 and F3) ﬁbrosis is present (3).
Liver biopsy (LB) has traditionally been considered the
gold standard for pretreatment evaluation of liver ﬁbrosis in
patients with chronic hepatitis C (CHC). However, LB is an
invasive procedure with several shortcomings (intra- and inter-
observer variability of histopathological interpretation, sam-
pling errors, high cost) and the risk of rare but potentially
life-threatening complications. In addition, LB is poorly
accepted by patients and it is not suitable for repeated evalua-
tion. Furthermore, the prevalence of CHC makes LB unrealis-
tic to be performed in all patients with this disease who are
candidates for antiviral therapy (4). This has raised the need
for developing other techniques that are less injurious and of
equal accuracy to skip the step of liver biopsy.
Some of the invented methods as aspartate transami-
nase/platelet ratio (APRI), abdominal ultrasonography mea-
suring caudate/right lobe ratio and hepatic stiffness
(Fibroscan) have been adopted to avoid biopsy.
In this study we evaluate the diagnostic accuracy and
clinical usefulness of ﬁbroscan in predicting two conditions –
signiﬁcant histological liver ﬁbrosis (METAVIRP F2) and
cirrhosis (F4) in patients with chronic viral hepatitis in
comparison to the liver biopsy.2. Patients and methods
The study was done on 50 chronic HCV patients with the age
of the patients ranging from 19 to 56 year old with mean age
37.6 ± 10 diagnosed by seropositivity for HCV antibodies
and HCV RNA by PCR. Patients were recruited from
NHTMRI outpatient clinics for assessment prior to
Interferon therapy. Inclusion and exclusion criteria are those
for interferon therapy.
Patients were subjected to the following:
1. Full history taking.
2. Clinical examination.Fig. 1 (a) Duplex image showed coarse hepatic echo-texture, wavy su
(b) Fibroscan score: F4 (34.3 K pascal).3. Laboratory investigations: CBC, AST, ALT, serum
bilirubin, serum albumin, prothrombin time, prothrom-
bin concentration &INR, viral markers HBs Ag, HCV
Ab and PCR of HCV.
4. Abdominal ultrasonography to assess the presence of
liver cirrhosis and ascites, portal vein and splenic size.
5. Liver stiffness measurement using the transient elas-
tography (ﬁbroscan) (Fig. 1).
6. Ultrasound guided liver biopsy was performed using a
semi-automatic true-cut needle (16 G) and liver biopsy
was ﬁxed in formalin and embedded in parafﬁn.
 Liver ﬁbrosis staging and activity grading was evaluated
according to the METAVIR scoring system. The used
ﬁbroscan device was (Echosens, Paris, France) located at
the NHTMRI done by the same expert with experience of
more than 500 cases.
 Fibrosis was staged on a 0–4 scale as follows: F0 = no ﬁbro-
sis; F1 = portal ﬁbrosis without septa; F2 = portal ﬁbrosis
with rare septa; F3 = numerous septa without cirrhosis;
and F4 = cirrhosis.
 Activity (A) was graded as follows: A0 = no histologic
necro-inﬂammatory activity; A1 = mild activity;
A2 = moderate activity; and A3 = severe activity. (The
French METAVIR Cooperative Study Group, 1994).
 Biopsy specimens were classiﬁed according to the length of
the specimen into three groups:1-Ideal biopsy: Specimen
lengthP 1.5 cm or the presence of 10 portal tracts,
2-Subideal biopsy: Specimen lengthP 1 and < 1.5withP 6
portal tracts and <10 portal tracts and 3-Not accepted <
1 cm.2.1. Ethical considerations
The patients gave a written consent for the procedures after
explaining the risk/beneﬁt ratio as well as expected hazards
and interventions.
2.2. Statistical analysis
Analysis of data was performed using SPSS 17 (Statistical
Package for Scientiﬁc Studies) for Windows. Description ofrface and patent PV with increased diameter and hepatofugal ﬂow.
Table 2 Degree of ﬁbrosis by ﬁbroscan and liver biopsy in the
studied group:
Fibroscan No and percent Liver biopsy No and percent
F0 8 (16%) F0 2 (4%)
F1 27 (54%) F1 32 (64%)
F2 6 (12%) F2 7 (14%)
F3 5 (10%) F3 6 (12%)
F4 4 (8%) F4 3 (6%)
Table 3 Activity grade among the studied group.
No. %
A0 3 6.0
A1 28 56.0
A2 13 26.0
A3 6 12.0
Table 4 Degree of agreement between ﬁbroscan and biopsy in
detecting ﬁbrosis stage.
Fibroscan Biopsy
F0 F1 F2 F3 F4
F0 2 6 0 0 0
F1 0 23 4 0 0
F2 0 3 3 0 0
F3 0 0 0 5 0
F4 0 0 0 1 3
Prospective comparison in chronic hepatitis C infection 295variables was presented as follows: Description of quantitative
variables was in the form of mean and Standard Deviation
(SD). Description of qualitative variables was in the form of
numbers (No.) and percents comparison between quantitative
variables was carried by Repeated measures Analysis of
Variance (ANOVA) test for comparing between more than
two groups of independent variables. Results were expressed
in the form of P-values.
3. Results
The study was carried on 50 patients with chronic HCV with
the age of the patients ranging from 19 to 56 year old with
mean age 37.6 ± 10. Concerning the hepatic function tests
total bilirubin were (0.74 mg/dl ± 0.25 mg/dl) AST level were
(50.4 ± 35.99), ALT level were (49.54 ± 36.98), serum albu-
min g/dl were (4.14 ± 0.36 g/dl) prothrombin concentration
were (87.7%± 10.9%) and INR (1.04 ± 0.21). Concerning
other lab ﬁnding TSH were (1.69 m IU/L ± 0.93), serum crea-
tinine were (0.83 mg /dl ± 0.19), serum HB were (13.67 g/
dl ± 1.43), platelets were (228,900 ± 61,900) and AFP were
ng/ml 5.97 ± 13.65 (Table 1).
There was positive correlation between the ﬁbroscan and
liver biopsy. In ﬁbroscan score 8 patients (16%) were F0, 27
patients (54%) were F1, 6 patients (12%) were F2, 5
patients(10%) were F3 and 4 patients (8%) were F4. In biopsy
3 patients (6%) were F0, 31 patients (62%) were F1, 7 patients
(14%) were F2, 6 patients (12%) were F3 and 3 patients (6%)
were F4. Comparing between F0 score of biopsy there was fair
agreement between ﬁbroscan and biopsy (the kappa measure
was 0.359). Comparison between F1 score of biopsy there alsoTable 1 Base line characters of the studied patients.
No (50)
Age 19–56(mean age 37.6 ± 10.5)
Sex
Female 18
Male 32
BMI (kg/m2) 26.36 (±3.2)
Total bilirubin mg/dl 0.74 (±0.25)
AST 50.4 (±35.99)
ALT 49.54 (±36.98)
Albumin g/dl 4.14 (± 0.36)
PC% 87.7 (±10.9)
INR 1.04 (±0.21)
TSH m IU/L 1.69(± 0.93)
AFP ng/ml 5.97 (±13.65)
Creatinine mg/dL 0.83 (± 0.19)
HB g/dl 13.67 (±1.43)
PLT * 103 228 (±61.9)
Ascites
No 50
Yes 0
Portal vein diameter
Average 42
Dilated 8
Peri-portal ﬁbrosis
No 47
Yes 3
Kappa measure of agreement = .478
P value < .001. There was a highly signiﬁcant agreement between 2
results of ﬁbroscan and biopsy.was moderate agreement between ﬁbroscan and biopsy (the
kappa measure was 0.468). Comparison between F2 score of
biopsy there also was moderate agreement between ﬁbroscan
and biopsy (the kappa measure were 0.482). Comparison
between F3 score of biopsy and ﬁbroscan there was high agree-
ment between ﬁbroscan and biopsy (the kappa measure was
0.737). Comparison between F4 score of biopsy and ﬁbroscan
there was moderate agreement between ﬁbroscan and biopsy
(the kappa measure was 0. 41). The overall relation between
all patients on all ﬁbrosis stages when comparing both ﬁbros-
can and biopsy was moderate agreement between both (the
kappa measure was 0.478). These results are illustrated in
Tables 2 and 4.
4. Discussion
Liver biopsy has a distinct advantage in that commonly asso-
ciated liver lesions, such as steatohepatitis and iron overload
which can impact on ﬁbrosis progression and treatment
response, can be diagnosed and investigated (5). However, it
also has its limitations in staging ﬁbrosis because of the hetero-
geneous distribution of ﬁbrosis in the liver and the moderate
reproducibility of readings. (6) (see Table 3 and 5)
Ultrasonic transient elastography (TE), enables to assess,
under active mechanical constraints, the elasticity of the liver,
Table 5 Relation between hepatic echo-texture and ﬁbroscan.
Fibrosis by ﬁbroscan Total P value
F0 F1 F2 F3 F4
Homogenous 2 7 1 0 0 10
25.0% 25.9% 16.7% .0% .0% 20.0% <.001
Bright 6 19 4 1 0 30
75.0% 70.4% 66.7% 20.0% .0% 60.0%
Coarse 0 1 1 4 4 10
.0% 3.7% 16.7% 80.0% 100.0% 20.0%
296 A.H.K. Abdelmaksoud et al.which correlates with hepatic ﬁbrosis stages. This technique is
routinely used in clinical practice to assess noninvasively liver
stiffness. The Fibroscan system generates a shear wave via an
impulse stress applied on the surface of the skin and records a
temporal series of radio-frequency (RF) lines using a single-
element ultrasound probe. Under the assumption of pure elas-
tic tissue, elasticity is proportional to the shear wave speed (7).
Fibroscan is a non-invasive test that assists liver stiffness by
employing vibration controlled transient elastography to emit
a shear wave through the liver and measure its velocity via
ultrasound (8).
Not only liver ﬁbrosis but also other factors contribute to
liver stiffness. Liver stiffness measurement (LSM) has been
consistently found to be falsely elevated in acute hepatitis,
manifested as alanine aminotransferase (ALT) ﬂares. Severe
hepatic necro-inﬂammation may lead to LSM values well
within the cirrhotic range, even in the absence of ﬁbrosis on
histology (9).
The main advantage of liver Fibroscan compared with
ﬁbrosis markers and biochemical scores is that it measures a
quantitative physical parameter directly on the liver and there
is no interference from extrahepatic disorders. It represents a
totally different approach and therefore could be complemen-
tary to the ﬁbrosis markers and biochemical scores to better
assess liver ﬁbrosis without using LB (10).
Halfon et al., (11) and Rossi et al., (12) found that, the
diagnostic performance of liver Fibroscan appears to be
equivalent to that of the best biochemical scores for patients
with signiﬁcant ﬁbrosis (FP 2) and appears to be better than
this test for the diagnosis of extensive ﬁbrosis (FP 3) and cir-
rhosis (F= 4).
Our study included 50 chronic HCV patients as diagnosed
by seropositivity for HCV antibodies and HCV RNA by
PCR. Patients were recruited from NHTMRI outpatient clin-
ics for assessment prior to INF therapy as a part of the
National program for treatment of viral hepatitis.
In the present study, there was a positive correlation
between ﬁbroscan and biopsy as follows: By ﬁbroscan score
8 patients (16%) were F0, 27 patients (54%) were F1, 6
patients (12%) were F2, 5 patients(10%) were F3 and 4
patients (8%) were F4. On liver biopsy, 3 patients (6%) were
F0, 31 patients (62%) were F1, 7 patients (14%) were F2, 6
patients (12%) were F3 and 3 patients (6%) were F4.
On comparing F0 score of biopsy there was fair agreement
between ﬁbroscan and biopsy (the kappa measure was 0.359).
Comparison between F1 score of biopsy showed moderate
agreement between ﬁbroscan and biopsy (the kappa measure
was 0.468). Comparison between F2 score of biopsy revealed
moderate agreement between ﬁbroscan and biopsy (the kappa
measure were 0.482). Comparison between F3 score of biopsyand ﬁbroscan had a high agreement between ﬁbroscan and
biopsy (the kappa measure was 0.737). On comparing between
F4 score of biopsy and ﬁbroscan there was moderate agree-
ment between ﬁbroscan and biopsy (the kappa measure was
0. 41).
The overall relation between all patients on all ﬁbrosis
stages when comparing both ﬁbroscan and biopsy was moder-
ate agreement between both (the kappa measure was 0.478).
This was similar to a study carried out by Rohit and his col-
leagues where there was signiﬁcant correlation between LSM
and histological ﬁbrosis (r = 0.58, P < 0.001) (13). In con-
trast, patients with high ﬁbroscan scores (n= 6; >11 kPa)
showed a severe form of liver ﬁbrosis with CLD and portal
hypertension from a clinical point of view in a study carried
out by Mun˜oz R and his colleagues (14).
One of the limitations to liver ﬁbroscan is ascites. Ascites is
a physical limitation to the technique because elastic waves do
not propagate through liquids. In addition, liver ﬁbroscan is
unsuccessful in patients with narrow intercostal spaces and
in patients with morbid obesity (15). None of our patients
had ascites and this is because they were selected from patients
awaiting assessment for pegylated interferon/ribavirin com-
bination therapy. None of our patients was morbidly obese
(all had BMI of 26.36 ± 3.2).
We also assessed the validity of ultrasonography in the
detection of ﬁbrosis in relation to ﬁbroscan and there was a
very high statistical signiﬁcance for the echotexture and the
degree of ﬁbrosis. Aube et al. (16) reported that ultra-
sonography had accuracy of 82%-88% to 100% in assessing
the diagnosis of cirrhosis. Its value is tempered by signiﬁcant
interobserver variability and an inability to gather all the
required measurements, because of technical limitations (17).
However, ultrasonography cannot quantify ﬁbrosis and accu-
rately diagnose it in the absence of the stigmata of cirrhosis
including shrunken liver and ascites which per se indicate cir-
rhosis and advanced ﬁbrotic process and hence not accepted
for assessment of hepatic ﬁbrosis in patients waiting for com-
bination therapy; instead it may be useful to exclude patients
with advanced cirrhosis from antiviral therapy (18).
To summarize, the correlation of liver biopsy with ﬁbroscan
score there was moderate agreement (matching) between liver
biopsy and ﬁbroscan; the highest matching in F3 and lowest in
F0, that means that ﬁbroscan has a good matching with liver
biopsy in detection hepatic ﬁbrosis and follow up of its
progression.
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